Related Experiment Video
Updated: Aug 14, 2026
Quantitative Assessment of Cortical Auditory-tactile Processing in Children with Disabilities
Published on: January 29, 2014
P1 latency as a biomarker for central auditory development in children with hearing impairment
Anu Sharma1, Kathryn Martin, Peter Roland
1Behavioral and Brian Sciences, Callier Advanced Hearing Research Center, University of Texas at Dallas 75235, USA. anu.sharma@utdallas.edu
Insights
The P1 cortical auditory-evoked potential (CAEP) latency serves as a biomarker for tracking central auditory pathway development in hearing-impaired children undergoing amplification. This objective measure aids clinicians in determining appropriate intervention, like cochlear implants, and monitoring auditory pathway maturation.
Area of Science:
- Neuroscience
- Audiology
- Developmental Pediatrics
Background:
- Central auditory pathway development is crucial for speech and language acquisition in children.
- Assessing auditory pathway maturation objectively is essential for guiding hearing interventions.
- Hearing aids and cochlear implants aim to provide adequate auditory stimulation for development.
Observation:
- The latency of the P1 cortical auditory-evoked potential (CAEP) was investigated as a biomarker.
- This biomarker was studied in three children with hearing impairment receiving amplification.
- The P1 CAEP latency reflects the functional maturation of the central auditory system.
Findings:
- P1 CAEP latency can serve as an objective clinical tool to evaluate sufficient acoustic stimulation.
- This biomarker helps assess the developmental trajectory of central auditory pathways.
- Sufficient stimulation is indicated by P1 CAEP latency within age-appropriate normative ranges.
Implications:
- Clinicians can confidently decide on cochlear implant candidacy after a hearing aid trial using P1 CAEP latency.
- This marker allows for monitoring auditory pathway maturation post-cochlear implantation.
- Objective electrophysiological measures like P1 CAEP latency enhance personalized hearing healthcare for children.
Abstract:
We used the latency of the P1 cortical auditory-evoked potential (CAEP) as a biomarker for the development of central auditory pathways in three children who received intervention through hearing aids and/or cochlear implants. Our goal was to examine the clinical feasibility of using the latency of the P1 CAEP as an objective tool to evaluate whether acoustic amplification for hearing-impaired children has provided sufficient stimulation for normal development of central auditory pathways. If clinicians have such a marker, then they can more confidently make a decision about whether to provide a child with a cochlear implant following an appropriate hearing-aid trial. Using the same marker, clinicians will also be able to monitor the maturation of central auditory pathways once electrical stimulation is initiated.
